Commonwealth Biotechnologies, Inc., through its subsidiaries, engages in the life sciences outsourcing business that offers discovery and development, and chemistry and biology products and services. It offers macromolecular synthetic and analytical services to researchers in the biotechnology industry or to researchers who are engaged in life sciences research in government or academic labs. The company provides drug discovery and pre-clinical services in the areas of genomics and proteomics serving the early stage research and development needs, as well as clinical trial support services; Bio-Safety Level 3 laboratory and CDC Registration in the area of bacterial and viral organisms, and a program in bio-threat toxin analysis; forensics, paternity, and convicted offender DNA index system services to government and private concerns; and research grade peptide synthesis and analysis. It serves private individuals, medical community, government, universities, legal community, and biotechnology and pharmaceutical companies. Commonwealth Biotechnologies has a strategic alliance with Genzyme Pharmaceuticals, as well as a joint venture agreement with Venturepharm Laboratories, Ltd. The company was founded in 1992 and is headquartered in Richmond, Virginia.